Active, not recruitingPhase 3NCT06060665
Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC)
Studying Primary biliary cholangitis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Gilead Sciences
- Principal Investigator
- Gilead Study DirectorGilead Sciences
- Intervention
- Seladelpar 10 mg(drug)
- Enrollment
- 90 target
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2023 – 2026
Study locations (30)
- The Institute for Liver Health II LLC dba Arizona Clinical Trials; Arizona Liver Health, Chandler, Arizona, United States
- California Liver Research Institute, Pasadena, California, United States
- University of California (UC) Davis Medical Center, Sacramento, California, United States
- California Pacific Medical Center, San Francisco, California, United States
- University of Colorado Denver - School of Medicine - Anschutz Medical Campus, Aurora, Colorado, United States
- South Denver Gastroenterology, Englewood, Colorado, United States
- Florida Research Institute, Lakewood Rch, Florida, United States
- University of Miami - Schiff Center for Liver Diseases, Miami, Florida, United States
- Gastro Health Research, Miami, Florida, United States
- Covenant Metabolic Specialists, LLC, Sarasota, Florida, United States
- Covenant Metabolic Specialists, LLC, Tampa, Florida, United States
- Digestive Healthcare of Georgia, Atlanta, Georgia, United States
- Northwestern Medicine Clinical Research Unit (CRU), Chicago, Illinois, United States
- Tulane University Medical Center, New Orleans, Louisiana, United States
- Louisiana Research Center, LLC, Shreveport, Louisiana, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06060665 on ClinicalTrials.govOther trials for Primary biliary cholangitis
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07449793Biochemical Response and Clinical Outcomes in Patients With PBCRenJi Hospital
- RECRUITINGPHASE3NCT07296458FIREFLY Trial: Fenofibrate Intervention---Randomized Evaluation in First-Line PBC TherapyXijing Hospital of Digestive Diseases
- RECRUITINGPHASE3NCT07282353A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCACascade Pharmaceuticals, Inc
- RECRUITINGNCT07205874Early Diagnosis of Primary Biliary Cholangitis (PBC) in Patients With Positive Anti-Mitochondrial Antibodies (AMA) and Normal Alkaline Phosphatase (ALP)Hospital Universitario La Paz
- ACTIVE NOT RECRUITINGNCT07049887A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria)Ipsen
- RECRUITINGNCT07149675PBC Long-term Outcomes StudyBeijing Friendship Hospital
- RECRUITINGEARLY PHASE1NCT07104201Fenofibrate in Subjects With Primary Biliary Cholangitis (PBC)Xijing Hospital of Digestive Diseases
- RECRUITINGNANCT06861465EMPower MechanismsUniversity of Alberta